Image by WangXiNa on Freepik
The UC Davis Comprehensive Cancer Center participated in a phase III clinical research to explore if the anti-cancer medication everolimus helped persons with kidney cancer. The clinical study findings revealed that many patients with kidney cancer survived for several years after undergoing surgery to remove the tumour.
The study also found that in a group of individuals at high risk of relapse, everolimus may have kept them cancer-free for a longer period of time. The findings were reported in The Lancet on July 28.
Primo “Lucky” Lara, Jr., Director of the Cancer Center, was a key investigator in the SWOG Cancer Research Network’s phase III S0931 experiment, better known as the EVEREST study.
Lara is SWOG’s deputy group chair and was recently appointed co-chair elect of the National Cancer Institute’s (NCI) cancer clinical trials group. Christopher W. Ryan, a SWOG investigator and professor of medicine at Oregon Health & Science University, led the study.
The study included patients from roughly 400 cancer centers around the country, including several from UC Davis Comprehensive Cancer Center. For 54 weeks, they were given 10 milligrams of oral everolimus or a placebo.
“Improvement was seen primarily in patients with very high-risk disease, while patients with intermediate high-risk disease saw no improvement,” Lara said. “This encouraging observation warrants further study. We must continue our work to discover and test new agents to improve outcomes in people with kidney cancer.”
Everolimus belongs to a class of drugs known as mTOR inhibitors, which prevent the growth of malignant cells.
Similar medicines are already being utilized to enhance the results of other cancer patients who have undergone surgery, including breast cancer patients.
The EVEREST trial enrolled 1,545 patients with intermediate high-risk or very high-risk renal cell carcinoma (cancer of the lining of the kidney tubes). Their cancer had all been medically removed with a partial or radical nephrectomy (kidney removal).
“Recurrence of cancer in these patients ranges from 2% to 40% following surgery,” Lara said. “It is important to test active new agents as part of clinical trials after their surgery and before their cancer returns and spreads.”
more recommended stories
Air Pollution Hurts Brain Health in Just 4 HoursAir Pollution Blurs the Mind, Impairs.
New therapies developed by Oxford experts offer online support for anxiety and post-traumatic stress disordersUrgent treatment solutions are needed for.
three key pillars to tackle antimicrobial resistance effectively — University of Oxford, Medical Sciences DivisionThe High-Level Meeting on antimicrobial resistance.
Oxford Vaccine Group marks 30 years battling ‘deadly six’ diseases with major art installation — University of Oxford, Medical Sciences DivisionThe installation was commissioned to mark.
Professor Ahmed Awarded Funding To Create World’s First Ovarian Cancer Prevention Vaccine — University of Oxford, Medical Sciences DivisionScientists at the University of Oxford,.
New research network unites Oxford University’s global fight against antimicrobial resistance — University of Oxford, Medical Sciences DivisionAntimicrobial resistance (AMR) threatens the foundation.
Typhoid vaccine trial confirms sustained protection for older children — University of Oxford, Medical Sciences DivisionThe TyVOID study, published in the Lancet, measured the.
Study Publishes New Insights on Goblet Cell Differentiation in Colorectal Cancer — University of Oxford, Medical Sciences DivisionThe research addresses the long-recognized poor.
Four Oxford researchers win prestigious Philip Leverhulme Prizes — University of Oxford, Medical Sciences DivisionOnly 30 prizes are awarded throughout.
Kavli Oxford’s Nick Gatford Wins Image of Distinction Award in Nikon Small World Competition — University of Oxford, Medical Sciences DivisionThe Nikon Small World competition, often.
Leave a Comment